Pavblu (Aflibercept-Ayyh) Patent Expiration, LOE Window & CMS Spending

Pavblu (Aflibercept-Ayyh) by Amgen: Biologic BLA (Purple Book Regime), 0 AB generics, $26K 2024 CMS Part D & Medicaid spend, and $1,665 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayB761298 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$26K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$26K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,665 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.